Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib-Reference-Cited by-同舟云学术

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

Published:2015-08-06 Issue:6 Volume:126 Page:790-797
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Patel Keyur P.¹,Newberry Kate J.²,Luthra Rajyalakshmi¹,Jabbour Elias²,Pierce Sherry²,Cortes Jorge²,Singh Rajesh¹,Mehrotra Meenakshi¹,Routbort Mark J.¹,Luthra Madan¹,Manshouri Taghi²,Santos Fabio P.³,Kantarjian Hagop²,Verstovsek Srdan²

Affiliation:

1. Departments of Hematopathology and

2. Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and

3. Hematology and Oncology Center, Hospital Israelita Albert Einstein, Sao Paulo, Brazil

Abstract

Key Points In patients treated with ruxolitinib, harboring ≥3 mutations was inversely correlated with spleen response and time to treatment discontinuation. Multigene profiling may be useful for therapeutic planning.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/6/790/1391035/790.pdf

Reference36 articles.

1. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.;Guglielmelli;Blood,2014

2. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.;Harrison;N Engl J Med,2012

3. Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms.;Tenedini;Leukemia,2014

4. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.;Engle;Leukemia

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Stem Cell Transplantation for Myelofibrosis;Current Hematologic Malignancy Reports;2024-09-06

2. Prognostic and Predictive Models in Myelofibrosis;Current Hematologic Malignancy Reports;2024-08-24

3. Value and limitations of targeted next-generation sequencing in idiopathic hypereosinophilia: an integrative diagnostic tool in challenging cases;Clinical and Experimental Medicine;2024-07-23

4. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature;Expert Opinion on Pharmacotherapy;2024-07-02

5. Пароксизмальная ночная гемоглобинурия и первичный миелофиброз — крайне редкое сочетание клональных заболеваний системы крови: обзор литературы и описание двух собственных клинических наблюдений из практики;Clinical Oncohematology;2024-04-01